Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-exon4, gB, pp150, and pp28 in healthy individuals:: Reevaluation of prevalence of IE1-specific CTLs

被引:105
作者
Gyulai, Z
Endresz, V
Burian, K
Pincus, S
Toldy, J
Cox, WI
Meric, C
Plotkin, S
Gönczöl, E
Berencsi, K
机构
[1] Wistar Inst, Philadelphia, PA 19104 USA
[2] Pasteu Merieux Connaught, Swiftwater, PA USA
[3] Virogenet Corp, Troy, NY 12180 USA
[4] Albert Szent Gyorgyi Med Univ, Dept Med Microbiol, H-6701 Szeged, Hungary
[5] Albert Szent Gyorgyi Med Univ, Natl Transfus Serv, S Hungarian Reg Blood Bank, H-6701 Szeged, Hungary
[6] Pasteur Merieux Connaught France, Marcy Letoile, France
关键词
D O I
10.1086/315445
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The prevalence of human cytomegalovirus (HCMV) pp65-, pp150-, IE1-exon4-, gB- and pp28-specific cytotoxic T lymphocyte (CTL) responses was compared among 34 healthy individuals, grouped by neutralizing antibody titers, Moderately and highly seropositive donors showed predominantly pp65- and IE1-exon4-specific CTL responses (92% and 76% of the donors, respectively), with similar precursor frequencies in the 2 donors tested. In addition, highly seropositive and a few moderately seropositive donors showed CTL responses to gB and pp150 (33% and 30% of the donors, respectively). No individual recognized pp28 as a target in the CTL assay. Phenotypic analysis revealed a mixed effector population of CD4(+) and CD8(+) (1 donor) or only CD8(+) cells for pp65-specific effectors (2 donors). IE1-exon4- and pp150-specific effecters were CD8(+) (2 donors and 1 donor, respectively), whereas gB-specific CTLs were CD4(+) (1 donor). These data may help to design a cellular immunity-based vaccine effective against HCMV disease.
引用
收藏
页码:1537 / 1546
页数:10
相关论文
共 40 条
[1]   THE STRUCTURE OF THE MAJOR IMMEDIATE EARLY GENE OF HUMAN CYTOMEGALO-VIRUS STRAIN AD169 [J].
AKRIGG, A ;
WILKINSON, GWG ;
ORAM, JD .
VIRUS RESEARCH, 1985, 2 (02) :107-121
[2]   FINE SPECIFICITY OF CELLULAR IMMUNE-RESPONSES IN HUMANS TO HUMAN CYTOMEGALOVIRUS IMMEDIATE-EARLY 1-PROTEIN [J].
ALP, NJ ;
ALLPORT, TD ;
VANZANTEN, J ;
RODGERS, B ;
SISSONS, JGP ;
BORYSIEWICZ, LK .
JOURNAL OF VIROLOGY, 1991, 65 (09) :4812-4820
[3]   Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells [J].
Boppana, SB ;
Britt, WJ .
VIROLOGY, 1996, 222 (01) :293-296
[4]   HUMAN CYTOMEGALOVIRUS-SPECIFIC CYTO-TOXIC T-CELLS - RELATIVE FREQUENCY OF STAGE-SPECIFIC CTL RECOGNIZING THE 72-KD IMMEDIATE EARLY PROTEIN AND GLYCOPROTEIN-B EXPRESSED BY RECOMBINANT VACCINIA VIRUSES [J].
BORYSIEWICZ, LK ;
HICKLING, JK ;
GRAHAM, S ;
SINCLAIR, J ;
CRANAGE, MP ;
SMITH, GL ;
SISSONS, JGP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (03) :919-931
[5]   Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection [J].
Diamond, DJ ;
York, J ;
Sun, JY ;
Wright, CL ;
Forman, SJ .
BLOOD, 1997, 90 (05) :1751-1767
[6]   Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization [J].
Endresz, V ;
Kari, L ;
Berencsi, K ;
Kari, C ;
Gyulai, Z ;
Jeney, C ;
Pincus, S ;
Rodeck, U ;
Méric, C ;
Plotkin, SA ;
Gönczöl, E .
VACCINE, 1999, 17 (01) :50-58
[7]   A novel mechanism for persistence of human cytomegalovirus in macrophages [J].
Fish, KN ;
Britt, W ;
Nelson, JA .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1855-1862
[8]   Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product [J].
Gilbert, MJ ;
Riddell, SR ;
Plachter, B ;
Greenberg, PD .
NATURE, 1996, 383 (6602) :720-722
[9]   SELECTIVE INTERFERENCE WITH CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX PRESENTATION OF THE MAJOR IMMEDIATE-EARLY PROTEIN FOLLOWING INFECTION WITH HUMAN CYTOMEGALOVIRUS [J].
GILBERT, MJ ;
RIDDELL, SR ;
LI, CR ;
GREENBERG, PD .
JOURNAL OF VIROLOGY, 1993, 67 (06) :3461-3469
[10]   PRECLINICAL EVALUATION OF AN ALVAC (CANARYPOX)-HUMAN CYTOMEGALOVIGRUS GLYCOPROTEIN-B VACCINE CANDIDATE [J].
GONCZOL, E ;
BERENCSI, K ;
PINCUS, S ;
ENDRESZ, V ;
MERIC, C ;
PAOLETTI, E ;
PLOTKIN, SA .
VACCINE, 1995, 13 (12) :1080-1085